| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 6 securities · passive | ||||||
|
Whitehawk Therapeutics, Inc.
13G
WHWK · 00032Q104
|
5.6% |
11/16/2026
Event 9/30/2026
|
||||
| Dellora Investments LP | 5.6% | |||||
| Kevin Pyun | 5.6% | |||||
|
Verrica Pharmaceuticals Inc.
13G
VRCA · 92511W207
|
5.2% |
11/16/2026
Event 9/30/2026
|
||||
| Dellora Investments LP | 5.2% | |||||
| Kevin Pyun | 5.2% | |||||
|
Tenax Therapeutics, Inc.
13G/A
TENX · 88032L605
|
6.4% |
10/9/2026
Event 10/2/2026
|
||||
| Dellora Investments Master Fund LP | 5.5% | |||||
| Dellora Investments LP | 6.4% | |||||
| Kevin Pyun | 6.4% | |||||
|
Rezolute, Inc.
13G
RZLT · 76200L309
|
5.9% |
8/12/2026
Event 8/5/2026
|
||||
| Dellora Investments Master Fund LP | 5.1% | |||||
| Dellora Investments LP | 5.9% | |||||
| Kevin Pyun | 5.9% | |||||
|
Palvella Therapeutics, Inc.
13G/A
PVLA · 697947109
|
1.3% |
12/17/2024
Event 12/13/2024
|
||||
| Dellora Investments Master Fund LP | 1.1% | |||||
| Dellora Investments LP | 1.3% | |||||
| Kevin Pyun | 1.3% | |||||
|
Pieris Pharmaceuticals, Inc.
13G/A
PIRS · 720795202
|
10.7% |
12/6/2024
Event 11/6/2024
|
||||
| Dellora Investments Master Fund LP | 9.3% | |||||
| Dellora Investments LP | 10.7% | |||||
| Kevin Pyun | 10.7% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.